Physician profile
Michael Brasher
NPI 1477073120
$1,170.20
in general payments reported to CMS, 2019-2025
14 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $515 · 2023: $379 · 2024: $42.74 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $423.82 | 2022-2023 | Floseal |
| Abbvie INC. | $176.57 | 2023-2025 | |
| Depuy Synthes Sales INC. | $107.75 | 2022-2023 | Matrixneuro, Synthecel |
| Abbott Laboratories | $79.18 | 2022-2025 | Eterna, Proclaim |
| Arbor Pharmaceuticals, INC. | $65.73 | 2021-2022 | |
| Lemaitre Vascular, INC. | $58.02 | 2022 | |
| Radius Health, INC. | $54.14 | 2021-2022 | |
| Stryker Corporation | $52.51 | 2022 | |
| Nevro Corp. | $37.44 | 2021 | |
| Medtronic, INC. | $36.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $31.00 | 2022-2023 | Andexxa |
| Merz Pharmaceuticals, LLC | $19.45 | 2022 | |
| Chiesi USA, INC. | $14.14 | 2024 | Cleviprex, Kengreal |
| Irras USA, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.